Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (341-350 of 418) with videos related to

Pageof 42
Sort By:
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Dermatology Online Journal|February 23, 2026
31-Gene expression profiling for cutaneous melanoma: an expert consensus panelJoshua Burshtein, Clay Cockerell, David Cotter, et al.
Dermatology and Therapy|February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Item-level psychometric properties for a new patient-reported psoriasis symptom diaryBruce E Strober, Judit Nyirady, Usha G Mallya, et al.
Journal of the American Academy of Dermatology|August 29, 2024
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvementMark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Pageof 42

Showing results (341-350 of 418) with videos related to

Sort By:
Pageof 42
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Dermatology Online Journal|February 23, 2026
31-Gene expression profiling for cutaneous melanoma: an expert consensus panelJoshua Burshtein, Clay Cockerell, David Cotter, et al.
Dermatology and Therapy|February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Item-level psychometric properties for a new patient-reported psoriasis symptom diaryBruce E Strober, Judit Nyirady, Usha G Mallya, et al.
Journal of the American Academy of Dermatology|August 29, 2024
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvementMark Lebwohl, Michael Bukhalo, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|July 17, 2017
Herpes zoster in psoriasis patients treated with tofacitinibKevin L Winthrop, Mark Lebwohl, Arnon D Cohen, et al.
Pageof 42